| Revenue growth | 16.6% YoY for FY26; 16.7% for Q4. |
|---|---|
| Margins | EBITDA margin up 83bps to 19.4% in FY26. |
| Order book | Healthy ARV orderbook; strategic contract prioritization. |
| Demand visibility | Strong international momentum; robust ARV orderbook. |
| Management confidence | High; delivered results in first year of 5-year roadmap. |
Growth
FY26 Revenue grew 16.6% to ₹9,204 Cr; Adjusted PAT rose 40.9% to ₹1,008 Cr.
Outlook
FY27 product registration for Lenacapavir (HIV); scaling complex injectables and biosimilars; 170bps ROCE improvement to 23.7%.
Risks
Domestic performance slowed due to portfolio reorganization; seasonality impact in Q4; R&D investment costs.
Earnings Call filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,950.60
- Market cap
- ₹37,005 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 36.6×Sector 50.4×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways
Emcure's Q1 FY27 results show strong performance driven by international markets and HIV (ARV) business, despite a transitional period in domestic operations following organizational restructuring and the acquisition of Sanofi and Roche portfolios.
- Call
- Guides 16% growth
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported Q1 FY27 revenue growth of 22.8% YoY with PAT margins expanding 110 bps. Growth was driven by a 34.2% surge in International Business (58% of total revenue).
Emcure Pharmaceuticals Q1 FY27 Results: Net Profit ₹292.5 Cr, Up 36.2% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,580 Cr (+22.8% YoY) and net profit of ₹292.5 Cr (+36.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹292.5 Cr · +36.2% YoY